FAMHL: Genetic Study of Families with Hodgkin Lymphoma

Genetic Study of Families with High Frequency of Hodgkin Lymphoma

Category:

Leukemia / Lymphoma

Diseases Treated:

Hodgkin lymphoma

Eligibility Overview:

  • 21 years of age or younger
  • Patient has a parent, sister, brother or child who also has Hodgkin lymphoma
  • Patient’s other family members who agree to participate

 

  1. Brief Summary

    Familial aggregation of Hodgkin lymphoma strongly suggests a genetic basis for HL risk. Current literature has reported an increased relative risk for family members and increased frequencies of various HLA antigens, but the exact cause and specific link for familial Hodgkin lymphoma is unknown. This study will perform genetic analysis on familiar Hodgkin lymphoma cases in which the disease affects more than one child in the family or parent and child. Researchers hope to identify genetic variation responsible for the multiple HL occurrences in these families, discover critical genetic defects or variations related to risk, and improve understanding of HL biology.

    Primary Objective

    • To perform whole exome sequencing of families with recurring Hodgkin lymphoma cases (affected as well as non-affected family members) to identify potential disease-causing germline genetic variations. 

    Eligibility Criteria

    Inclusion criteria include:

    • 21 years of age or younger
    • Diagnosis of Hodgkin lymphoma with a first-degree relative also diagnosed with HL
    • Family members of the patient, either affected or unaffected by a malignancy, who agree to participate in the study

    Study Sites

    St. Jude Children’s Research Hospital
    Memphis, Tennessee

  2. About this study

    Hodgkin lymphoma is a cancer of the white blood cells in the lymph nodes. Research has shown that Hodgkin lymphoma may run in families.

    This study will look at patients with Hodgkin lymphoma and their close relatives who may also have the disease. Researchers will examine samples of saliva or blood to learn more about changes in genes that may be related to this disease in families. The body has about 20,000 different genes that play different roles. When a change, or mutation, occurs in a gene, it sometimes increases your risk of developing a disease like Hodgkin lymphoma.

    Purpose of this observational study

    The main goal of this study is to learn more about what causes Hodgkin lymphoma and why some people and families may have a higher risk of developing the disease. The results of the study may help researchers identify better treatments for patients with Hodgkin lymphoma.

    Eligibility overview

    • 21 years of age or younger
    • Patient has a parent, sister, brother or child who also has Hodgkin lymphoma
    • Other family members who agree to participate 
  3. FAMHL Quick View
    Sponsors St. Jude Children’s Research Hospital
    ClinicalTrials.gov identifier NCT02795013
    Trial start date June 2016
    Estimated enrollment 50
    Study type Observational
    Conditions Hodgkin lymphoma
    Ages 21 years old or younger (patient); any age (family)
    Principal investigator Jamie Flerlage, MD
    Study sites St. Jude Children’s Research Hospital 
    For a consultation or to discuss FAMHL St. Jude Physician/Patient Referral Office
    1-888-226-4343
    referralinfo@stjude.org

Contact

Jamie Flerlage, MD

St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105  USA
Voice: 1-888-226-4343 or 901-595-4055
24-Hour Emergency Access Pager: 1-800-349-4334

Referring or consulting clinicians only: protocolinfo@stjude.org
For all other inquiries about St. Jude Children's Research Hospital studies: referralinfo@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.